{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T14:08:15Z","timestamp":1788962895305,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"GSK"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drug Saf"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40264-026-01685-3","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T13:53:29Z","timestamp":1784037209000},"page":"1199-1210","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Enhancing Disease Surveillance and Pharmacovigilance Practices for RTS,S\/AS01E Malaria Vaccine Rollout in Ghana, Kenya, and Malawi: Strategies, Impact, Challenges, and Lessons Learned"],"prefix":"10.1007","volume":"49","author":[{"given":"Val\u00e9rie","family":"Haine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tene-Alima","family":"Essoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline Perrin","family":"Franck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miloje","family":"Savic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"1685_CR1","first-page":"225","volume":"99","author":"World Health Organization","year":"2024","unstructured":"World Health Organization. Malaria vaccine: WHO position paper \u2013 May 2024. Wkly Epidemiol Rec. 2024;99:225\u201348.","journal-title":"Wkly Epidemiol Rec"},{"key":"1685_CR2","unstructured":"European Medicines Agency. First malaria vaccine receives positive scientific opinion from EMA. 2015. https:\/\/www.ema.europa.eu\/en\/news\/first-malaria-vaccine-receives-positive-scientific-opinion-ema. Accessed 10 Nov 2025."},{"key":"1685_CR3","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/s0140-6736(15)60721-8","volume":"386","author":"RTS,S Clinical Trials Partnership","year":"2015","unstructured":"RTS,S Clinical Trials Partnership. Efficacy and safety of RTS,S\/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial. Lancet. 2015;386:31\u201345. https:\/\/doi.org\/10.1016\/s0140-6736(15)60721-8.","journal-title":"Lancet"},{"key":"1685_CR4","doi-asserted-by":"publisher","first-page":"2386","DOI":"10.1080\/21645515.2019.1586040","volume":"15","author":"YG Mendoza","year":"2019","unstructured":"Mendoza YG, Garric E, Leach A, Lievens M, Ofori-Anyinam O, Pir\u00e7on JY, et al. Safety profile of the RTS,S\/AS01 malaria vaccine in infants and children: additional data from a phase III randomized controlled trial in sub-Saharan Africa. Hum Vaccin Immunother. 2019;15:2386\u201398. https:\/\/doi.org\/10.1080\/21645515.2019.1586040.","journal-title":"Hum Vaccin Immunother"},{"key":"1685_CR5","first-page":"33","volume":"91","author":"World Health Organization","year":"2016","unstructured":"World Health Organization. Malaria vaccine: WHO position paper \u2013 January 2016. Wkly Epidemiol Rec. 2016;91:33\u201351.","journal-title":"Wkly Epidemiol Rec"},{"key":"1685_CR6","unstructured":"World Health Organization. Full evidence report on the RTS,S\/AS01 malaria vaccine. 2021. https:\/\/cdn.who.int\/media\/docs\/default-source\/immunization\/mvip\/full-evidence-report-on-the-rtss-as01-malaria-vaccine-for-sage-mpag-(sept2021).pdf. Accessed 23 Mar 2026."},{"key":"1685_CR7","unstructured":"World Health Organization. Malaria: The malaria vaccine implementation programme (MVIP). 2020. https:\/\/www.who.int\/news-room\/questions-and-answers\/item\/malaria-vaccine-implementation-programme. Accessed 10 Nov 2025."},{"key":"1685_CR8","doi-asserted-by":"publisher","first-page":"e995","DOI":"10.1016\/s2214-109x(25)00096-8","volume":"13","author":"V Haine","year":"2025","unstructured":"Haine V, Oneko M, Debois M, Ndeketa L, Agyapong PD, Boahen O, et al. Safety of RTS,S\/AS01E malaria vaccine up to 1 year after the third dose in Ghana, Kenya, and Malawi (EPI-MAL-003): a phase 4 cohort event monitoring study. Lancet Glob Health. 2025;13:e995\u20131005. https:\/\/doi.org\/10.1016\/s2214-109x(25)00096-8.","journal-title":"Lancet Glob Health"},{"key":"1685_CR9","first-page":"60","volume":"97","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Malaria vaccine: WHO position paper \u2013 March 2022. Wkly Epidemiol Rec. 2022;97:60\u201378.","journal-title":"Wkly Epidemiol Rec"},{"key":"1685_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-022-04144-3","volume":"21","author":"N Praet","year":"2022","unstructured":"Praet N, Asante KP, Bozonnat MC, Akit\u00e9 EJ, Ansah PO, Baril L, et al. Assessing the safety, impact and effectiveness of RTS,S\/AS01E malaria vaccine following its introduction in three sub-Saharan African countries: methodological approaches and study set-up. Malar J. 2022;21:132. https:\/\/doi.org\/10.1186\/s12936-022-04144-3.","journal-title":"Malar J"},{"key":"1685_CR11","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-021-03670-w","volume":"20","author":"RTS,S Epidemiology EPI-MAL-002 Study Group","year":"2021","unstructured":"RTS,S Epidemiology EPI-MAL-002 Study Group. Baseline incidence of meningitis, malaria, mortality and other health outcomes in infants and young sub-Saharan African children prior to the introduction of the RTS,S\/AS01E malaria vaccine. Malar J. 2021;20:197. https:\/\/doi.org\/10.1186\/s12936-021-03670-w.","journal-title":"Malar J"},{"key":"1685_CR12","doi-asserted-by":"publisher","first-page":"e859","DOI":"10.1016\/s2214-109x(25)00022-1","volume":"13","author":"KP Asante","year":"2025","unstructured":"Asante KP, Bozonnat MC, Savic M, Owusu-Agyei S, Kaali S, Otieno W, et al. Incidence rates of malaria, meningitis, and mortality in children younger than 5 years: a prospective cohort study in Ghana and Kenya before the roll-out of the RTS,S\/AS01E malaria vaccine from 2016 to 2022. Lancet Glob Health. 2025;13:e859\u201369. https:\/\/doi.org\/10.1016\/s2214-109x(25)00022-1.","journal-title":"Lancet Glob Health"},{"key":"1685_CR13","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1111\/bcp.15193","volume":"89","author":"R Kiguba","year":"2023","unstructured":"Kiguba R, Olsson S, Waitt C. Pharmacovigilance in low- and middle-income countries: a review with particular focus on Africa. Br J Clin Pharmacol. 2023;89:491\u2013509. https:\/\/doi.org\/10.1111\/bcp.15193.","journal-title":"Br J Clin Pharmacol"},{"key":"1685_CR14","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1586\/17512433.2015.1053391","volume":"8","author":"S Olsson","year":"2015","unstructured":"Olsson S, Pal SN, Dodoo A. Pharmacovigilance in resource-limited countries. Expert Rev Clin Pharmacol. 2015;8:449\u201360. https:\/\/doi.org\/10.1586\/17512433.2015.1053391.","journal-title":"Expert Rev Clin Pharmacol"},{"key":"1685_CR15","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1080\/14740338.2023.2251375","volume":"22","author":"HB Ndagije","year":"2023","unstructured":"Ndagije HB, Walusimbi D, Atuhaire J, Ampaire S. Drug safety in Africa: a review of systems and resources for pharmacovigilance. Expert Opin Drug Saf. 2023;22:891\u20135. https:\/\/doi.org\/10.1080\/14740338.2023.2251375.","journal-title":"Expert Opin Drug Saf"},{"key":"1685_CR16","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40264-015-0387-4","volume":"39","author":"HH Ampadu","year":"2016","unstructured":"Ampadu HH, Hoekman J, de Bruin ML, Pal SN, Olsson S, Sartori D, et al. Adverse Drug Reaction reporting in Africa and a comparison of individual case safety report characteristics between Africa and the rest of the world: Analyses of spontaneous reports in VigiBase\u00ae. Drug Saf. 2016;39:335\u201345. https:\/\/doi.org\/10.1007\/s40264-015-0387-4.","journal-title":"Drug Saf"},{"key":"1685_CR17","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s40264-020-00925-4","volume":"43","author":"V Jusot","year":"2020","unstructured":"Jusot V, Chimimba F, Dzabala N, Menang O, Cole J, Gardiner G, et al. Enhancing pharmacovigilance in sub-Saharan Africa through training and mentoring: A GSK pilot initiative in Malawi. Drug Saf. 2020;43:583\u201393. https:\/\/doi.org\/10.1007\/s40264-020-00925-4.","journal-title":"Drug Saf"},{"key":"1685_CR18","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1186\/s12889-022-13867-6","volume":"22","author":"JU Stegmann","year":"2022","unstructured":"Stegmann JU, Jusot V, Menang O, Gardiner G, Vesce S, Volpe S, et al. Challenges and lessons learned from four years of planning and implementing pharmacovigilance enhancement in sub-Saharan Africa. BMC Public Health. 2022;22:1568. https:\/\/doi.org\/10.1186\/s12889-022-13867-6.","journal-title":"BMC Public Health"},{"key":"1685_CR19","doi-asserted-by":"publisher","first-page":"867","DOI":"10.2165\/00002018-200831100-00005","volume":"31","author":"E Sevene","year":"2008","unstructured":"Sevene E, Mariano A, Mehta U, Machai M, Dodoo A, Vilardell D, et al. Spontaneous adverse drug reaction reporting in rural districts of Mozambique. Drug Saf. 2008;31:867\u201376. https:\/\/doi.org\/10.2165\/00002018-200831100-00005.","journal-title":"Drug Saf"},{"key":"1685_CR20","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1007\/s40264-023-01368-3","volume":"47","author":"YG Mendoza","year":"2024","unstructured":"Mendoza YG, Jusot V, Adou F, Ota M, Elenge DM, Begum T, et al. Enhancing pharmacovigilance in C\u00f4te d\u2019Ivoire: Impact of GSK\u2019s training and mentoring pilot project in the Abidjan region. Drug Saf. 2024;47:147\u201359. https:\/\/doi.org\/10.1007\/s40264-023-01368-3.","journal-title":"Drug Saf"},{"key":"1685_CR21","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1016\/s0140-6736(24)00004-7","volume":"403","author":"KP Asante","year":"2024","unstructured":"Asante KP, Mathanga DP, Milligan P, Akech S, Oduro A, Mwapasa V, et al. Feasibility, safety, and impact of the RTS,S\/AS01E malaria vaccine when implemented through national immunisation programmes: evaluation of cluster-randomised introduction of the vaccine in Ghana, Kenya, and Malawi. Lancet. 2024;403:1660\u201370. https:\/\/doi.org\/10.1016\/s0140-6736(24)00004-7.","journal-title":"Lancet"},{"key":"1685_CR22","unstructured":"The RAFT network. https:\/\/raft.network\/en. Accessed 10 Nov 2025."},{"key":"1685_CR23","first-page":"81","volume":"97","author":"World Health Organization","year":"2022","unstructured":"World Health Organization. Global Advisory Committee on Vaccine Safety, 10 August 2021; Global Advisory Committee on Vaccine Safety, 15 December 2021. Wkly Epidemiol Rec. 2022;97:81\u201396.","journal-title":"Wkly Epidemiol Rec"},{"key":"1685_CR24","doi-asserted-by":"publisher","first-page":"126","DOI":"10.3389\/fpubh.2014.00126","volume":"2","author":"L Bonnardot","year":"2014","unstructured":"Bonnardot L, Liu J, Wootton E, Amoros I, Olson D, Wong S, et al. The development of a multilingual tool for facilitating the primary-specialty care interface in low resource settings: the MSF tele-expertise system. Front Public Health. 2014;2:126. https:\/\/doi.org\/10.3389\/fpubh.2014.00126.","journal-title":"Front Public Health"},{"key":"1685_CR25","doi-asserted-by":"publisher","first-page":"21465","DOI":"10.3402\/gha.v6i0.21465","volume":"6","author":"V Patterson","year":"2013","unstructured":"Patterson V, Wootton R. A web-based telemedicine system for low-resource settings 13 years on: insights from referrers and specialists. Glob Health Action. 2013;6:21465. https:\/\/doi.org\/10.3402\/gha.v6i0.21465.","journal-title":"Glob Health Action"},{"key":"1685_CR26","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1258\/135763307781644951","volume":"13","author":"THF Broens","year":"2007","unstructured":"Broens THF, Huis in\u2019t Veld RMHA, Vollenbroek-Hutten MMR, Hermens HJ, van Halteren AT, Nieuwenhuis LJM. Determinants of successful telemedicine implementations: a literature study. J Telemed Telecare. 2007;13:303\u20139. https:\/\/doi.org\/10.1258\/135763307781644951.","journal-title":"J Telemed Telecare"},{"key":"1685_CR27","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1002\/pds.5542","volume":"32","author":"ER Parracha","year":"2023","unstructured":"Parracha ER, Advinha AM, Lopes MJ, Oliveira-Martins S. Mobile apps for quick adverse drug reaction report: A scoping review. Pharmacoepidemiol Drug Saf. 2023;32:19\u201327. https:\/\/doi.org\/10.1002\/pds.5542.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1685_CR28","doi-asserted-by":"publisher","DOI":"10.2196\/46694","volume":"25","author":"C Perrin Franck","year":"2023","unstructured":"Perrin Franck C, Babington-Ashaye A, Dietrich D, Bediang G, Veltsos P, Gupta PP, et al. iCHECK-DH: guidelines and checklist for the reporting on digital health implementations. J Med Internet Res. 2023;25:e46694. https:\/\/doi.org\/10.2196\/46694.","journal-title":"J Med Internet Res"},{"key":"1685_CR29","doi-asserted-by":"publisher","DOI":"10.2196\/39775","volume":"7","author":"SB Dolan","year":"2023","unstructured":"Dolan SB, Wittenauer R, Shearer JC, Njoroge A, Onyango P, Owiso G, et al. Integration of a digital health intervention into immunization clinic workflows in Kenya: qualitative, realist evaluation of technology usability. JMIR Form Res. 2023;7:e39775. https:\/\/doi.org\/10.2196\/39775.","journal-title":"JMIR Form Res"},{"key":"1685_CR30","unstructured":"World Health Organization. List of National Regulatory Authorities (NRAs) operating at maturity level 3 (ML3) and maturity level 4 (ML4) as benchmarked against WHO Global Benchmarking Tool (GBT). 2026. https:\/\/www.who.int\/publications\/m\/item\/list-of-nras-operating-at-ml3-and-ml4. Accessed 24 March 2026."},{"key":"1685_CR31","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1007\/s40264-018-0730-7","volume":"42","author":"V Kalaiselvan","year":"2019","unstructured":"Kalaiselvan V, Srivastava S, Singh A, Gupta SK. Pharmacovigilance in India: present scenario and future challenges. Drug Saf. 2019;42:339\u201346. https:\/\/doi.org\/10.1007\/s40264-018-0730-7.","journal-title":"Drug Saf"},{"key":"1685_CR32","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s40264-014-0222-3","volume":"37","author":"L Zhang","year":"2014","unstructured":"Zhang L, Wong LYL, He Y, Wong ICK. Pharmacovigilance in China: current situation, successes and challenges. Drug Saf. 2014;37:765\u201370. https:\/\/doi.org\/10.1007\/s40264-014-0222-3.","journal-title":"Drug Saf"},{"key":"1685_CR33","doi-asserted-by":"publisher","first-page":"e1761","DOI":"10.1016\/s2214-109x(25)00299-2","volume":"13","author":"R Kiguba","year":"2025","unstructured":"Kiguba R, Ndagije HB, Mwebaza N, Ssenyonga R, Giibwa L, Isabirye G, et al. Adverse drug reaction reporting with the Med Safety app in Uganda: a cluster-randomised, controlled trial. Lancet Glob Health. 2025;13:e1761\u201370. https:\/\/doi.org\/10.1016\/s2214-109x(25)00299-2.","journal-title":"Lancet Glob Health"},{"key":"1685_CR34","doi-asserted-by":"publisher","unstructured":"Edlund SB, Davis MA, Kaufman JH. The spatiotemporal epidemiological modeler. Proceedings of the 1st ACM International Health Informatics Symposium; 2010; Arlington, Virginia, USA: Association for Computing Machinery; 2010. p. 817\u201320. https:\/\/doi.org\/10.1145\/1882992.1883115.","DOI":"10.1145\/1882992.1883115"}],"container-title":["Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01685-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40264-026-01685-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40264-026-01685-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T13:12:06Z","timestamp":1788959526000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40264-026-01685-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":34,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["1685"],"URL":"https:\/\/doi.org\/10.1007\/s40264-026-01685-3","relation":{},"ISSN":["0114-5916","1179-1942"],"issn-type":[{"value":"0114-5916","type":"print"},{"value":"1179-1942","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"24 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All authors were involved in the planning and conduct of the work described in this paper. All authors contributed to the writing and granted their final approval of the manuscript before submission. All authors had final responsibility for the decision to submit for publication.\u00a0All authors read and approved the final version.\u00a0","order":1,"name":"Ethics","label":"Author Contributions","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"VH and MS are employed by GSK and hold financial equities in GSK. CPF declares receiving grants from the Swiss Agency for Development and Cooperation and support from the World Health Summit Foundation for attending meetings or travel. T-AE has no financial relationships to disclose. The authors declare no other non-financial relationships and activities or conflicts of interest.","order":2,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Data sharing is not applicable as no new data were created or analyzed for this study.","order":3,"name":"Ethics","label":"Availability of Data and Material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not use personal data.","order":4,"name":"Ethics","label":"Ethics Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not use personal data.","order":5,"name":"Ethics","label":"Consent To Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study did not use personal data.","order":6,"name":"Ethics","label":"Consent For Publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":7,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Mosquirix\n                      and AS01 are trademarks owned by or licensed to the GSK group of companies.","order":8,"name":"Ethics","label":"Trademark Statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}